PharmaCyte Biotech, Inc. (PMCB): Cash & Equivalents
$18.60M
As of 2026-04-30
$17.74M
As of 2026-07-31
-35.1%
3-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2026-04-30 | $18.60M | +22.6% | 2026-07-29, Balance as of period end |
| 2025-04-30 | $15.17M | -69.8% | 2026-07-29, Balance as of period end |
| 2024-04-30 | $50.18M | -26.2% | 2025-08-11, Balance as of period end |
| 2023-04-30 | $68.04M | -20.3% | 2024-08-13, Balance as of period end |
| 2022-04-30 | $85.40M | n/a | 2023-07-31, Balance as of period end |
| No annual figure between 2013-04-30 and 2022-04-30. | |||
| 2013-04-30 | $199.3K | n/m | 2013-07-29, Balance as of period end |
| 2012-04-30 | $15.7K | -72.5% | 2013-07-29, Balance as of period end |
| 2011-04-30 | $57.2K | n/a | 2012-08-14, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| PharmaCyte Biotech, Inc. (PMCB) | 2026-04-30 | $18.60M | +22.6% |
| Amgen Inc (AMGN) | 2025-12-31 | $9.13B | -23.8% |
| Repligen Corp (RGEN) | 2025-12-31 | $566.02M | -25.3% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $264.71M | +63.2% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $40.79M | -10.9% |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $89.74M | -14.3% |
| Vericel Corp (VCEL) | 2025-12-31 | $100.09M | +34.3% |
| Neurocrine Biosciences Inc (NBIX) | 2025-12-31 | $713.00M | +206.0% |
| Exelixis, Inc. (EXEL) | 2026-01-02 | $482.49M | +122.0% |
Compare PMCB, AMGN, RGEN, TECH side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗